Selumetinib in Children With Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma Without NF1
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A Phase 2 Trial of Selumetinib in Children With Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma Without NF1: A Pediatric Brain Tumor Consortium Study
Neuro-oncology 2021 Feb 25;[EPub Ahead of Print], J Fangusaro, A Onar-Thomas, TY Poussaint, S Wu, AH Ligon, N Lindeman, O Campagne, A Banerjee, S Gururangan, L Kilburn, S Goldman, I Qaddoumi, P Baxter, G Vezina, C Bregman, Z Patay, JY Jones, CF Stewart, MJ Fisher, LA Doyle, M Smith, IJ Dunkel, M FouladiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.